{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:09:52Z","timestamp":1790096992021,"version":"4.0.1"},"reference-count":93,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"publisher","award":["DS 701"],"award-info":[{"award-number":["DS 701"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"publisher","award":["DS 702"],"award-info":[{"award-number":["DS 702"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]},{"award":["DS 701"],"award-info":[{"award-number":["DS 701"]}],"id":[{"id":"https:\/\/ror.org\/016f61126","id-type":"ROR","asserted-by":"publisher"}]},{"award":["DS 702"],"award-info":[{"award-number":["DS 702"]}],"id":[{"id":"https:\/\/ror.org\/016f61126","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>This article describes the synthesis, structure confirmation, and evaluation of physico-chemical, pharmacological, and pharmacokinetic properties of new para-fluorophenylated dihydroimidazotriazinones. Based on the strategy of heteroannulation, and the concept of fluorine\u2013hydrogen isosterism, an efficient and simple synthetic route was developed. The target heterobicycles (10\u201318) were obtained by the reaction of nucleophilic building blocks, i.e., 1-(R-phenyl)-2-hydrazinylideneimidazolidine hydroiodides (1\u20139), with an electrophilic two-carbon synthon, i.e., 2-(4-fluorophenyl)-2-oxoacetic acid. The structures of the new compounds were confirmed by spectroscopic data. The spectrum of anticancer activity, selectivity profile, and effect on caspase levels, as well as the haemolytic and antihaemolytic properties of the molecules were assessed in in vitro and ex vivo studies. Most compounds exhibited antiproliferative activity against human solid tumour and leukaemic cells (superior\/comparable to anticancer drugs) with low toxicity to normal cells. Moreover, they revealed a broader spectrum of anticancer activity than previously obtained isosteres without fluorine substitution, suggesting that the isosteric replacement of hydrogen with fluorine was a fruitful modification. The most selective molecules were able to increase the levels of apoptotic caspases in lung, cervical, and breast cancer cells. Molecular docking results revealed that although all fluorophenylated fused triazinones exhibited affinity for the adenosine A2A and A2B receptors, ligands 13, 16, and 17 emerged as promising dual-target candidates due to their superior interaction profiles and stronger binding affinities for both receptor subtypes. All the compounds proved to be safe for red blood cells, as they did not induce any haemolytic effects. Additionally, most of them revealed protective effects on oxidatively stressed erythrocytes, and their antihaemolytic activity was better or comparable to that of antioxidant standards. In silico ADME (absorption, distribution, metabolism, excretion) profiling demonstrated favourable drug-like and pharmacokinetic properties of compounds. Lipophilicity of the molecules was measured by RP-HPLC on an ODS-2 column using an appropriately selected mobile phase. The retention factors, logs k, for most compounds showed a strong correlation with both in silico log P (logarithmic n-octanol\/water partition coefficient) and log PHSA (logarithmic human serum albumin\/water partition coefficient) values. In summary, among the nine original fluorophenylated fused 1,2,4-triazinones studied, five molecules (11, 13, 14, 15, and 17) seem to be the most promising anticancer drug candidates suitable for further development.<\/jats:p>","DOI":"10.3390\/ijms27188388","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:32:12Z","timestamp":1790083932000},"page":"8388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Fluorophenylated Dihydroimidazotriazinones as Potential Anticancer Agents: Design, Synthesis, In Vitro, Ex Vivo and In Silico Characterisation"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1576-097X","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Sztanke","sequence":"first","affiliation":[{"name":"Department of Medical Chemistry, Medical University of Lublin, 4A Chod\u017aki Street, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"given":"Jolanta","family":"Rzymowska","sequence":"additional","affiliation":[{"name":"Department of Biology and Genetics, Medical University of Lublin, 4A Chod\u017aki Street, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Ma\u0142gorzata","family":"Janicka","sequence":"additional","affiliation":[{"name":"Department of Physical Chemistry, Institute of Chemical Science, Faculty of Chemistry, Maria Curie-Sk\u0142odowska University, Maria Curie-Sk\u0142odowska Sq. 3, 20-031 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Weronika","family":"Sofi\u0144ska-Chmiel","sequence":"additional","affiliation":[{"name":"Analytical Laboratory, Institute of Chemical Science, Faculty of Chemistry, Maria Curie-Sk\u0142odowska University, Maria Curie-Sk\u0142odowska Sq. 3, 20-031 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-5245","authenticated-orcid":false,"given":"Krzysztof","family":"Sztanke","sequence":"additional","affiliation":[{"name":"Laboratory of Bioorganic Compounds Synthesis and Analysis, Medical University of Lublin, 4A Chod\u017aki Street, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"ref_1","unstructured":"Wermuth, C.G. (1996). The Practice of Medicinal Chemistry, Academic Press."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Patrick, G.L. (2023). An Introduction to Medicinal Chemistry, Oxford University Press Inc.","DOI":"10.1093\/hesc\/9780198866664.001.0001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1021\/cr4002879","article-title":"Fluorine in pharmaceutical industry: Fluorine-containing drugs introduced to the market in the last decade (2001\u20132011)","volume":"114","author":"Wang","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_6","first-page":"30","article-title":"Fluorine: The new kingpin of drug discovery","volume":"30","author":"Wang","year":"2012","journal-title":"Chim. Oggi-Chem. Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jfluchem.2006.01.011","article-title":"Fluorine in medicinal chemistry: A review of anti-cancer agents","volume":"127","author":"Isanbor","year":"2006","journal-title":"J. Fluor. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103480","DOI":"10.1016\/j.bioorg.2019.103480","article-title":"Two novel classes of fused azaisocytosine-containing congeners as promising drug candidates: Design, synthesis as well as in vitro, ex vivo and in silico studies","volume":"95","author":"Sztanke","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.bmcl.2009.07.036","article-title":"Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones","volume":"19","author":"Sztanke","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejps.2019.02.033","article-title":"The influence of some promising fused azaisocytosine-containing congeners on zebrafish (Danio rerio) embryos\/larvae and their antihaemolytic, antitumour and antiviral activities","volume":"132","author":"Sztanke","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_11","first-page":"335","article-title":"Anticancer active trifluoromethylated fused triazinones are safe for early-life stages of zebrafish (Danio rerio) and reveal a proapoptotic action","volume":"6","author":"Sztanke","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sztanke, M., Rzymowska, J., and Sztanke, K. (2022). Anti-tumor active isopropylated fused azaisocytosine-containing congeners are safe for developing Danio rerio as well as red blood cells and activate apoptotic caspases in human breast carcinoma cells. Molecules, 27.","DOI":"10.3390\/molecules27041211"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Aapro, M.S. (1994). Innovative Antimetabolites in Solid Tumours, Springer.","DOI":"10.1007\/978-3-642-79200-7"},{"key":"ref_14","unstructured":"Sztanke, K. (2012). New 1-Substituted-2-hydrazino-4,5-dihydroimidazole Hydroiodides and Method for Their Obtaining. (Polish Patent PL 211550 B1)."},{"key":"ref_15","unstructured":"Sztanke, M., and Sztanke, K. (2023). 3-(4-Fluorophenyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one Derivatives Substituted with Phenyl, Alkylphenyl, Dialkylphenyl and Alkoxyphenyl, Method for Their Preparation and Medical Use. (Polish Patent PL 243307 B1)."},{"key":"ref_16","unstructured":"Sztanke, M., and Sztanke, K. (2023). 3-(4-Fluorophenyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-ones Substituted with Monochlorophenyl or Dichlorophenyl, Method of Their Preparation and Medical Use. (Polish Patent PL 243308 B1)."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.7717\/peerj-ochem.4","article-title":"New insights into the mechanism of Schiff base synthesis from aromatic amines in the absence of acid catalyst or polar solvents","volume":"2","author":"Silva","year":"2020","journal-title":"PeerJ Org. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/ie950529i","article-title":"Integration of wiped-film evaporation and crossflow microfiltration for the purification of a silylenol ether reaction mixture: Process issues and scaleup","volume":"35","author":"Larson","year":"1996","journal-title":"Ind. Eng. Chem. Res."},{"key":"ref_19","unstructured":"Oki, M. (1985). Applications of Dynamic NMR Spectroscopy to Organic Chemistry, VCH Publishers."},{"key":"ref_20","unstructured":"Silverstein, R.M., Webster, F.X., Kiemle, D.J., and Bryce, D.L. (2014). Spectrometric Identification of Organic Compounds, John Wiley & Sons. [8th ed.]."},{"key":"ref_21","unstructured":"Friebolin, H. (2010). Basic One- and Two-Dimensional NMR Spectroscopy, Wiley-VCH. [5th ed.]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1021\/jo060205b","article-title":"Rotation in biphenyls with a single ortho-substituent","volume":"71","author":"Mazzanti","year":"2006","journal-title":"J. Org. Chem."},{"key":"ref_23","unstructured":"G\u00fcnther, H. (2013). NMR Spectroscopy: Basic Principles, Concepts and Applications in Chemistry, Wiley-VCH. [3rd ed.]."},{"key":"ref_24","first-page":"283","article-title":"Crystal structure of 8-(4-methylphenyl)-3-(propan-2-yl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one: A potential antitumor agent","volume":"79","author":"Mazur","year":"2022","journal-title":"Acta Pol. Pharm.\u2013Drug Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0040-4020(75)80056-1","article-title":"The infrared spectra of fused 1,2,4-triazin-5-ones","volume":"31","author":"Taylor","year":"1975","journal-title":"Tetrahedron"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmech.2019.05.067","article-title":"Anti-cancer effects of cinnamon: Insights into its apoptosis effects","volume":"178","author":"Sadeghi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/cdd.2014.216","article-title":"Old, new and emerging functions of caspases","volume":"22","author":"Shalini","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-immunol-073119-095439","article-title":"Caspases in cell death, inflammation, and pyroptosis","volume":"38","author":"Kesavardhana","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"118688","DOI":"10.1016\/j.bbamcr.2020.118688","article-title":"Targeting apoptotic caspases in cancer","volume":"1867","author":"Boice","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. ImmunoTher. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/acs.chemrev.6b00119","article-title":"Structurally enabled discovery of adenosine A2A receptor antagonists","volume":"117","author":"Jazayeri","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","article-title":"Targetting cancer-derived adenosine: New therapeutic approaches","volume":"4","author":"Young","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbi.2011.10.004","article-title":"A novel fused 1,2,4-triazine derivative as antioxidant and nonselective antagonist of adenosine A2A receptors in ethanol-activated liver stellate cells","volume":"195","author":"Sztanke","year":"2012","journal-title":"Chem.-Biol. Interact."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/jm201177b","article-title":"3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A novel template for the design of highly selective A2B adenosine receptor antagonists","volume":"55","author":"Taliani","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41421-022-00503-1","article-title":"Structures of adenosine receptor A 2B R bound to endogenous and synthetic agonists","volume":"8","author":"Cai","year":"2022","journal-title":"Cell Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhang, J., Yan, W., Duan, W., W\u00fcthrich, K., and Cheng, J. (2020). Tumor immunotherapy using A2A adenosine receptor antagonists. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090237"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106962","DOI":"10.1016\/j.esmoop.2026.106962","article-title":"First-in-human study of the dual A2A\/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors","volume":"11","author":"Siu","year":"2026","journal-title":"ESMO Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/1535-7163.MCT-23-0843","article-title":"Dual A2A\/A2B adenosine receptor antagonist M1069 counteracts immunosuppressive mechanisms of adenosine and reduces tumor growth in vivo","volume":"23","author":"Schiemann","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"W463","DOI":"10.1093\/nar\/gkaf361","article-title":"PLIP 2025: Introducing protein\u2013protein interactions to the protein\u2013ligand interaction profiler","volume":"53","author":"Schake","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.str.2017.06.012","article-title":"Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity","volume":"25","author":"Cheng","year":"2017","journal-title":"Structure"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev-pharmtox-032112-135923","article-title":"Structure-function of the G protein-coupled receptor superfamily","volume":"53","author":"Katritch","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1016\/j.ejmech.2010.04.039","article-title":"Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods","volume":"45","author":"Cheng","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zelepuga, E.A., Chingizova, E.A., Menchinskaya, E.S., Pislyagin, E.A., Avilov, S.A., Kalinin, V.I., Aminin, D.L., and Silchenko, A.S. (2025). Anticancer Activity of Triterpene Glycosides Cucumarioside A0-1 and Djakonovioside A Against MDA-MB-231 as A2B Adenosine Receptor Antagonists. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110327"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/cbf.3135","article-title":"The use of erythrocyte fragility to assess xenobiotic cytotoxicity","volume":"33","author":"Pagano","year":"2015","journal-title":"Cell Biochem. Funct."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"S\u00e6b\u00f8, I.P., Bj\u00f8r\u00e5s, M., Franzyk, H., Helgesen, E., and Booth, J.A. (2023). Optimization of the hemolysis assay for the assessment of cytotoxicity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032914"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"S\u00e9guy, L., Groo, A.-C., Goux, D., Hennequin, D., and Malzert-Fr\u00e9on, A. (2020). Design of non-haemolytic nanoemulsions for intravenous administration of hydrophobic APIs. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121141"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8831545","DOI":"10.1155\/2020\/8831545","article-title":"Determination of the cytotoxic effect of different leaf extracts from Parinari curatellifolia (Chrysobalanaceae)","volume":"2020","author":"Kundishora","year":"2020","journal-title":"J. Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"632971","DOI":"10.1155\/2014\/632971","article-title":"A time-dose model to quantify the antioxidant responses of the oxidative hemolysis inhibition assay (OxHLIA) and its extension to evaluate other hemolytic effectors","volume":"2014","author":"Prieto","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_55","unstructured":"(2026, May 25). Available online: http:\/\/www.organic-chemistry.org\/prog\/peo\/."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1586\/ecp.13.15","article-title":"The potential and promise of mefenamic acid","volume":"6","author":"Cimolai","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1007\/BF00778304","article-title":"Mefenamic acid\u2013A nonsteroid antiinflammatory agent","volume":"11","author":"Trinus","year":"1977","journal-title":"Pharm. Chem. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2016.08.023","article-title":"Gemcitabine treatment promotes pancreatic cancer stemness through the Nox\/ROS\/NF-\u03baB\/STAT3 signaling cascade","volume":"382","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2246","DOI":"10.1038\/cddis.2016.157","article-title":"Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy","volume":"7","author":"Fan","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME\u2013Tox)","volume":"13","author":"Sarkadi","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Alici, H. (2025). Structure-based design and in-silico evaluation of computationally proposed curcumin derivatives as potential inhibitors of the coronaviral PLpro enzymes. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060798"},{"key":"ref_62","unstructured":"(2026, May 28). Available online: https:\/\/biosig.lab.uq.edu.au\/pkcsm\/."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s002280100369","article-title":"In vitro prediction of gastrointestinal absorption and bioavailability: An experts\u2019 meeting report","volume":"57","author":"Pelkonen","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13318-019-00602-7","article-title":"Evaluation of the role of P-glycoprotein (P-gp)-mediated efflux in the intestinal absorption of common substrates with elacridar, a P-gp inhibitor, in rats","volume":"45","author":"Suzuki","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kono, Y., Kawahara, I., Shinozaki, K., Nomura, I., Marutani, H., Yamamoto, A., and Fujita, T. (2021). Characterization of P-glycoprotein inhibitors for evaluating the effect of P-glycoprotein on the intestinal absorption of drugs. Pharmaceutics, 1.","DOI":"10.3390\/pharmaceutics13030388"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1021\/acs.jcim.8b00934","article-title":"Predicting skin permeability by means of computational approaches: Reliability and caveats in pharmaceutical studies","volume":"59","author":"Pecoraro","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tox.2017.06.008","article-title":"Quantitative structure-skin permeability relationships","volume":"387","author":"Tsakovska","year":"2017","journal-title":"Toxicology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejps.2010.10.011","article-title":"Use of unbound volumes of drug distribution in pharmacokinetic calculations","volume":"42","author":"Stepensky","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jmgm.2010.03.010","article-title":"Prediction of passive blood-brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors","volume":"28","author":"Vilar","year":"2010","journal-title":"J. Mol. Graph. Model."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/17425247.2013.762354","article-title":"Drug targeting to brain: A systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB","volume":"10","author":"Nagpal","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jinorgbio.2018.03.002","article-title":"Membrane-attached mammalian cytochromes P450: An overview of the membrane\u2019s effects on structure, drug binding, and interactions with redox partners","volume":"183","author":"Bazgier","year":"2018","journal-title":"J. Inorg. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Moussaoui, M., Baammi, S., Baassi, M., Kerraj, S., Soufi, H., Rachdi, Y., Idrissi, M.E., Salah, M., Belghiti, M.E., and Daoud, R. (2026). In Silico development of novel quinazoline-based EGFR inhibitors via 3D-QSAR, docking, ADMET, and molecular dynamics. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27021050"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejps.2010.03.014","article-title":"Renal excretion of clofarabine: Assessment of dose-linearity and role of renal transport systems on drug excretion","volume":"40","author":"Ajavon","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cpdd.339","article-title":"Mechanisms and consequences of drug-drug interactions","volume":"6","author":"Greenblatt","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","article-title":"Clearance in drug design","volume":"62","author":"Smith","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpba.2012.09.006","article-title":"Chromatographic retention parameters in correlation analysis with in silico biological descriptors of novel series of N-phenyl-3-methyl succimide derivatives","volume":"72","author":"Kaliszan","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_80","unstructured":"(2025, May 15). VCCLAB, Virtual Computational Chemistry Laboratory. Available online: https:\/\/www.vcclab.org."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10822-005-8694-y","article-title":"Virtual computational chemistry laboratory\u2013design and description","volume":"19","author":"Tetko","year":"2005","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/jps.10494","article-title":"Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol\/water and immobilized artificial membrane lipophilicity","volume":"92","author":"Nunhuck","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9673(99)01202-9","article-title":"Lipophilicity characterization by reversed-phase liquid chromatography of some furan derivatives","volume":"869","author":"Cimpan","year":"2000","journal-title":"J. Chromatogr. A"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9780470125885.ch5","article-title":"Computational approaches to lipophilicity: Methods and applications","volume":"Volume 11","author":"Lipkowitz","year":"1997","journal-title":"Reviews in Computational Chemistry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejps.2007.04.003","article-title":"Comparison between immobilized artificial membrane (IAM) HPLC data and lipophilicity in n-octanol for quinolone antibacterial agents","volume":"31","author":"Barbato","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0021-9673(95)00523-4","article-title":"Quantitative structure-retention relationships in the examination of the topography of the binding site of antihistamine drugs on alpha 1-acid glycoprotein","volume":"722","author":"Kaliszan","year":"1996","journal-title":"J. Chromatogr. A"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/bmc.1130080306","article-title":"Quantitative relationships between the structure of beta-adrenolytic and antihistamine drugs and their retention on an alpha 1-acid glycoprotein HPLC column","volume":"8","author":"Nasal","year":"1994","journal-title":"Biomed. Chromatogr."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/cr068412z","article-title":"QSRR: Quantitative structure-(chromatographic) retention relationships","volume":"107","author":"Kaliszan","year":"2007","journal-title":"Chem. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0169-7439(02)00107-7","article-title":"Projection methods in chemistry","volume":"65","author":"Daszykowski","year":"2003","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0003-2697(90)90310-6","article-title":"An enzyme-linked immunosorbent assay for bromodeoxyuridine incorporation using fixed microcultures","volume":"185","author":"Muir","year":"1990","journal-title":"Anal. Biochem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0022-1759(91)90377-R","article-title":"Measurement of antigen specific lymphocyte proliferation using 5-bromodeoxyuridine incorporation: An easy and low cost alternative to radioactive thymidine incorporation","volume":"140","author":"Huong","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0022-1759(88)90276-1","article-title":"Detection of human white cell proliferative responses by immunoenzymatic measurement of bromodeoxyuridine uptake","volume":"10","author":"Magaud","year":"1988","journal-title":"J. Immunol. Methods"},{"key":"ref_93","first-page":"1","article-title":"pKa, log Poct and HPLC capacity factor on a porous polymer gel in the study of a series of 2-benzamido-5-nitrothiazoles","volume":"17","author":"Bollinger","year":"1998","journal-title":"Quant. Struct.-Act. Relat."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:34:46Z","timestamp":1790094886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":93,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188388"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188388","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}